Lloyds ADR: http://www.investorrelations.lloydstsb.com/ir/adr_information_page.asp Lloyds TSB shares are traded in the USA through a New York Stock Exchange-listed sponsored ADR facility with The Bank of New York as the depositary. The ADRs are traded on the New York Stock Exchange under the symbol LYG. The CUSIP number is 539439109 and the ratio of ADRs to ordinary shares is 1:4. Email enquiries: shareowners@bankofny.com or go to www.adrbny.com . To view ADR dividend history go to US Dividend History. ****** http://www.adrbnymellon.com/dr_profile.jsp?cusip=539439109 http://www.ft.com/cms/s/0/a9a28bf6-dac1-11de-933d-00144feabdc0.html?nclick_check=1 More than 99 per cent of investors approved plans to raise £22.5bn through a rights issue and debt swap, allowing Lloyds to break free from the governmentâs asset protection scheme Investors are being offered 1.34 shares for each existing one they own at 37p a share.
http://www.ft.com/cms/s/0/91d746b8-d938-11de-b2d5-00144feabdc0.html The worldâs largest rights issue got off the ground as Lloyds Banking Group set the pricing for £13.5bn of new shares ahead of a crucial shareholder vote in Birmingham on Thursday. Investors, who are being offered 1.34 new shares for each existing one they own at 37p a share, are expected to vote in favour and, bar a small percentage of the bankâs extensive private shareholder base, are set to take up their rights over the next fortnight. The price of the new shares works out at a 39 per cent discount to the so-called theoretical ex-rights price, which takes into account the dilutive effect of the issue on the bankâs overall market capitalisation. The offerwill run until December 11. Providing that investors approve the fundraising on Thursday they will have two weeks in which they can trade their rights in the market before the new shares start trading on December 14. http://www.adrbnymellon.com/files/AD27365.pdf
http://www.reuters.com/article/marketsNews/idCNGEE5AN0KZ20091124?rpc=44 Nov 24 (Reuters) - Britain's Lloyds Banking Group Plc (LLOY.L) has priced the world's largest rights issue, worth 13.5 billion pounds ($22.3 billion). [ID:nGEE5AM0R8] Following are key points on the cash call: STATISTICS * Issue price per new share of 37p * To offer 1.34 new shares for every existing share * Issue price represents 59.5 percent discount to Nov. 23 close of 91.47p * 38.6 percent discount to theoretical ex rights price based on Nov. 23 close * More than 36.5 billion shares will be offered * New shares will represent 57.3 percent of enlarged share capital of the group RETAIL SHAREHOLDERS * Lloyds has Britain's largest retail shareholder base * Estimates the total cost for average private shareholder of 366.67 pounds if they take up all their rights TIMETABLE * General shareholder meeting Nov 26 * Dealing in nil-paid rights begins Nov 27 * Results of U.S. debt exchange offer Dec 9 * Last date for rights issue acceptance Dec 11 * New ordinary shares begin trading Dec 14
previous close Thu 26 November LLOY 88.83 pence adjusted previous close Thu 26 November LLOY 59.15 pence
18 May 2009 article about LLOY rights issue http://www.thisismoney.co.uk/investing/article.html?in_article_id=485585&in_page_id=166 3 June 2009 article about LLOY rights issue http://www.thisismoney.co.uk/investing/article.html?in_article_id=487283&in_page_id=166 Shareholders can buy 0.6213 new shares for each Lloyds share they hold. Although the final deadline for the deal is Friday, many stockbrokers are imposing shorter deadlines for their clients. Friday = 5 June 2009
interesting chart that shows strong positive correlation between: 1. Nikkei and 2. The SPX/gold ratio http://www.zerohedge.com/article/does-nikkei-foreshadow-10-drop-sp http://www.zerohedge.com/sites/default/files/images/user5/imageroot/geithner/Nikkei 12.2.jpg
Since this post, a decline in the JPY versus the USD resulted in a boost to the Nikkei. And what do you know, the SPX/gold ratio went up a bit too.
Although Citron Research dot com (previously "stocklemon") has highlighted some companies that (as yet) have not collapsed, they have been on to some winners in recent years. The best example that comes to mind is HSOA. Today AMED is down about 8% on heavy volume. It has been highlighted several times on Citron Research. The reason for the decline today? Probably this story: http://www.tampabay.com/news/federal-medicare-fraud-task-force-expands-into-tampa/1059041 Or this one: HHS Expands Fraud Task Forces: Baton Rouge, Brooklyn, and Tampa 2009-12-15 21:36:07.351 GMT Sheryl R. Skolnick Ph.D. Pali Capital Inc. 212-259-2649 Secretary of Health and Human Services Sebelius announced today that the agency's very successful anti-Medicare fraud joint efforts with the Justice Department in south Florida are to be expanded to three new sites: Baton Rouge, Louisiana; Brooklyn, NY and Tampa, Florida. Home health agencies have been a major focus of the task forces' efforts in south Florida as fraud appears to have run rampant in that market. None of the publicly traded companies have been named in any of the indictments or arrests so far, including 5 unsealed indictments and 25 arrests just today. We find that interesting because two of the four publicly traded home health companies are based in or near Baton Rouge, i.e., Amedisys (AMED, Not Rated) and LHC Group (LHCG, Not Rated) and because Louisiana seems to have a plethora of home health agencies.
Citigroup raised $20.5 billion in order to repay $20 billion in TARP preferred securities http://finance.yahoo.com/news/CORRECTING-and-REPLACING-Citi-bw-42778016.html?x=0&.v=2 As at time of writing, Citi shares outstanding is 22.86B * $3.45 = market cap of $78.87 billion which does not include the 5.4 billion common shares sold in this offering. Common stock sold was 5.4 billion * $3.15 = $17.010 billion
Government common stock ownership is 7.7 billion shares: http://www.zerohedge.com/article/so...-offloaded-over-12-months-after-investors-bal http://www.citigroup.com/citi/corporategovernance/tarp.htm http://www.citigroup.com/citi/corporategovernance/data/tarp/tarp_pr_3q09.pdf 7.692 million shares @ $3.25 in exchange for the old $25 billion preferred stock (refer press releases from 23 July 2009 to 30 July 2009) see also http://www.citigroup.com/citi/fin/data/p091214a.pdf